Is it reasonable that each pediatric investigation plan required of drug developers under the EU Paediatric Regulation should cost companies an additional €20m or so in R&D and administrative fees? Should biosimilars makers continue to be exempted from obligations under the regulation?
And given that around 45% of companies fail to benefit from one of the rewards offered by the regulation to...







